Non-COVID approvals and advice you may have missed in 2021

December 30, 2021

2 minutes to read

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

Unsurprisingly, many of our most read stories in 2021 were about the COVID-19 pandemic. Stories about COVID-19 vaccines and therapies were popular, especially those about approvals, clearances or recommendations.

Below, we’ve listed nine stories about approvals or recommendations issued in 2021 that did not relate to COVID-19.

Sign outside the FDA headquarters in Washington, DC.
Source: Adobe Stock.

ACIP recommends universal hepatitis B vaccination for adults aged 19 to 59

In November, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend vaccination against the hepatitis B virus for all adults between the ages of 19 and 59. The recommendation said that adults in this age group – as well as adults aged 60 and over with risk factors – “should” be vaccinated against HBV. He said adults aged 60 or older who do not have known risk factors for HBV infection “can” be vaccinated against HBV. Read more.

CDC Says All Sexually Active Patients Should Be Informed About HIV Preperation

The CDC has recommended that all sexually active adult and adolescent patients be informed about HIV PrEP. In an updated clinical practice guideline, the CDC also added a recommendation for prescribing long-acting cabotegravir for PrEP even before it was approved. Read more.

‘Historic moment’: WHO recommends childhood malaria vaccine

In October, WHO recommended the widespread use of a malaria vaccine in children in sub-Saharan Africa and other areas heavily affected by the mosquito-borne disease, which kills more than 400,000 people a year. . Read more.

ACIP Unanimously Recommends Dengue Vaccine For Children 9-16 Years Old

In June, ACIP voted unanimously to recommend the use of a three-dose dengue vaccine approved for children aged 9 to 16 who live in endemic areas by a 14-0 vote. . In addition, the committee also recommended that the vaccine be covered by the Vaccines for Children program. Read more.

FDA approves Merck’s 15-valent pneumococcal vaccine

In July, the FDA approved Vaxneuvance, Merck’s 15-valent pneumococcal conjugate vaccine, for adults 18 years of age or older. Read more.

CDC Updates STI Treatment Guidelines For First Time Since 2015

Also in July, the CDC released updated clinical guidelines for the treatment of STIs amid a sustained national increase in cases of chlamydia, gonorrhea and syphilis. The guide, updated for the first time since 2015, also included prevention strategies and diagnostic recommendations. Read more.

FDA approves Pfizer’s first tick-borne encephalitis vaccine in the United States

In August, Pfizer’s Ticovac, a vaccine against tick-borne encephalitis, was approved by the FDA – the first such vaccine to be approved in the United States. Read more.

FDA Extends Cell-Based Influenza Vaccine Approval To 6 Months Of Age

The FDA has expanded the age indication of the only cell-based inactivated influenza vaccine approved for use in the United States to include children as young as 6 months old, the vaccine’s maker announced in October. Read more.

CDC Advisory Committee Updates Recommendations for Pneumococcus and Shingles Vaccines

ACIP has made new recommendations for vaccinating adults against pneumococcus and shingles. Read more.

Comments are closed.